TaGeza Biopharmaceuticals
Antibodies to Cancer Stem Cell Receptors
Health Tech & Life Sciences
Non Active, Sep 2023 ceased to operate
Company Overview
Snapshot
Founded in February 2014 by Nadav Peles and Orit Harari-Steinberg, TaGeza Biopharmaceuticals operates with 1–10 employees. The company secured seed funding in January 2019 from aMoon Fund, marking a key milestone in its development.
Business overview
TaGeza Biopharmaceuticals is a biotechnology startup focused on the study of cancer stem cells in aggressive forms of cancer. The company's core technology involves identifying central markers of highly aggressive cancer stem cells and developing drugs to target them, aiming to eradicate treatment-resistant cancers. Operating in the Health Tech & Life Sciences sector, TaGeza serves global markets within the pharmaceuticals and laboratories industries.
Company Intelligence Q&A
- What is TaGeza Biopharmaceuticals' primary focus?
- TaGeza Biopharmaceuticals is dedicated to studying cancer stem cells in the deadliest forms of cancer, with the goal of identifying central markers and developing targeted drugs to eradicate treatment-resistant cancers.
- When was TaGeza Biopharmaceuticals founded?
- TaGeza Biopharmaceuticals was founded in February 2014.
- Who are the founders of TaGeza Biopharmaceuticals?
- TaGeza Biopharmaceuticals was co-founded by Nadav Peles and Orit Harari-Steinberg.
- What is the company's current operational status?
- TaGeza Biopharmaceuticals is currently non-active, having ceased operations in September 2023.
- What was a significant early milestone for TaGeza Biopharmaceuticals?
- In January 2019, TaGeza Biopharmaceuticals secured seed funding from aMoon Fund.